Trastuzumab: is the new evidence revolutionary?
Artículo
en Inglés
| IMSEAR
| ID: sea-111421
ABSTRACT
A few years back, the survival benefit of trastuzumab in HER 2 positive breast cancer patients presenting with metastatic disease was proven in a randomized setting. Recently a number of randomized trials have reported their results in the adjuvant setting in HER 2 positive patients. These trials have been considered by some as a landmark in the evolution of breast cancer management. Although the data is encouraging, it need to be seen in a proper perspective keeping in mind the limitations and the side effects reported. This article stresses the use of Herceptin in carcinoma breast patients in adjuvant setting with a cautionary eye.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Asunto principal:
Neoplasias de la Mama
/
Femenino
/
Humanos
/
Ensayos Clínicos Controlados Aleatorios como Asunto
/
Quimioterapia Adyuvante
/
Receptor ErbB-2
/
Anticuerpos Monoclonales
/
Antineoplásicos
Tipo de estudio:
Ensayo Clínico Controlado
Idioma:
Inglés
Año:
2006
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS